Page 1 of 1

Table 5

Evaluation of AHRQ's Pharmaceutical Outcomes Portfolio

Table 5: Level 1 Findings: Trends

VanderbiltPediatricPrescription rates of antipsychotic drugs for children with less severe afflictions are increasing, especially for ADHD and depression. It's not really known if the benefits to the children outweigh the risks. A study to determine if benefits outweigh the risks is needed.
Duke Annual prevalence of use for [life saving cardiovascular therapies] increased between 1995 and 2002
DukeCardiac patientsResults of project looking at overall use of anti-arrhythmic drugs in the era of increased use of ICDs demonstrated increased use of anti-arrhythmic drugs despite, or potentially due to, the increased use of ICDs during this time.
AlabamaPatients with GIOP & ProvidersStudy provided evidence at a national level of poor quality of care and substantial practice pattern variation amenable to provider-targeted interventions aimed at improving GIOP prevention.
UNCPediatricFirst round findings confirmed increasing use of psychotropics by youths in IPA-model health plans, with consistency across health plans in different geographic regions. Prescribing physician is a significant factor.
VanderbiltHIVRetrospective study of prescribing rates of contraindicated combinations protease inhibitors and statins in HIV-infected people to asses impact of publications of treatment guides. Contraindicated combinations have decreased, but remain unacceptably high.

Return to Contents
Proceed to Table 6


Page last reviewed December 2007
Internet Citation: Table 5: Evaluation of AHRQ's Pharmaceutical Outcomes Portfolio. December 2007. Agency for Healthcare Research and Quality, Rockville, MD.